Breast cancers can be characterized as HR positive (either single or double HR positive), human epidermal growth factor receptor 2 (HER2) positive, or triple negative, and the type of cancer determines the anticancer treatment modalities and also predicts tumor sensitivity to pharmacological therapies as well as patient prognosis. The gene discussed is ERBB2; the disease is breast cancer.